Nutriband Reports 41% Revenue Growth in Q2 2025, Despite Net Loss

Nutriband Inc. has reported its financial results for the three and six months ended July 31, 2025, revealing a significant increase in revenue compared to the same period last year. The company generated $622,452 in revenue for the three months ending July 31, 2025, up from $442,830 in the prior year, marking a 41% increase. For the six-month period, revenue rose to $1,289,884 from $851,362, representing a 51% increase. Despite this growth, Nutriband reported a net loss of $2,000,337 for the quarter and $3,389,206 for the six months, compared to losses of $1,705,465 and $3,603,542, respectively, in the prior year.

The company's operational expenses have also seen a notable rise, with selling, general, and administrative expenses increasing to $1,597,540 for the three months ended July 31, 2025, compared to $737,325 in the same period last year. This increase is attributed primarily to higher compensation and legal expenses. Research and development costs for the Aversa Fentanyl product were $562,554 for the quarter, down from $773,975 in the previous year, reflecting a shift in focus and reduced labor costs. The company’s total costs and expenses for the quarter amounted to $2,625,665, leading to a loss from operations of $2,003,213.

In terms of strategic developments, Nutriband has made significant strides in its product pipeline, particularly with its Aversa Fentanyl product, which is being developed in partnership with Kindeva Drug Delivery. The company has formalized its exclusive product development partnership with Kindeva, which includes shared development costs and milestone payments. Additionally, Nutriband issued a preferred stock dividend of 3,008,642 shares of Series A Convertible Preferred Stock, valued at $21,814,166, to shareholders on August 5, 2025.

As of July 31, 2025, Nutriband reported cash and cash equivalents of $6,995,101, an increase from $4,311,719 at the beginning of the year. The company’s working capital also improved to $5,948,628 from $3,811,420. The increase in cash flow is attributed to financing activities, including $5,305,503 from the exercise of warrants. Nutriband continues to rely on equity financing and debt to support its operations, as it has not yet achieved profitability.

Looking ahead, Nutriband's management remains optimistic about its operational outlook, citing expectations for increased demand for its products and ongoing development efforts. The company plans to continue focusing on its Aversa product line and aims to file for FDA approval in 2026. However, management acknowledges the inherent risks associated with drug development and the need for additional funding to support its growth initiatives.